Meeder Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Meeder Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	–	–	2203
2022 Q3	$0	Hold	5	–	–	﹤0.01%	2459
2022 Q2	$0	Hold	5	–	–	﹤0.01%	2534
2022 Q1	$0	Buy	+5	New	–	﹤0.01%	2600
2021 Q4	–	Sell	-5	Closed	–	–	2579
2021 Q3	$0	Hold	5	–	–	﹤0.01%	2731
2021 Q2	$0	Buy	+5	New	–	﹤0.01%	2760
2021 Q1	–	Sell	-1,138	Closed	-$1K	–	2521
2020 Q4	$1K	Buy	+1,138	New	+$2.42K	﹤0.01%	1800
2020 Q2	–	Sell	-3,727	Closed	-$14K	–	2675
2020 Q1	$14K	Sell	3,727 -43	-1%	-$142	﹤0.01%	1391
2019 Q4	$11K	Buy	+3,770	New	+$9.8K	﹤0.01%	1546

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Meeder Asset Management's BMY.RT Position: Q4 2022 in Review

Meeder Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2022, closing a stake of 5 shares.

Meeder Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 8 quarters. The position peaked at $14K in Q1 2020. 2 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2022.

Meeder Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 5 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2022.
Meeder Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 8 quarters.
Meeder Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $14K in Q1 2020.
2 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.